Related Experiment Video

Updated: Jun 13, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial

Helge Røsjø1, Serge Masson, Roberto Latini

  • 1Division of Medicine, Akershus University Hospital, Lørenskog, Norway.

European Journal of Heart Failure
|April 15, 2010
PubMed

Insights

Chromogranin A (CgA) levels in chronic heart failure (HF) patients are linked to mortality risk factors but do not offer additional prognostic value beyond standard assessments. Further research is needed for CgA in HF management.

Area of Science:

  • Cardiology
  • Biomarkers
  • Clinical Research

Background:

  • Chronic heart failure (HF) remains a leading cause of mortality worldwide.
  • Identifying reliable prognostic biomarkers is crucial for optimizing HF patient management.
  • Chromogranin A (CgA) is a neuroendocrine peptide whose role in HF prognosis is under investigation.

Purpose of the Study:

  • To evaluate the association between circulating chromogranin A (CgA) levels and clinical outcomes in a large cohort of patients with chronic heart failure (HF).
  • To determine if CgA provides incremental prognostic information beyond established risk factors in HF.

Main Methods:

  • Plasma CgA levels were measured in 1233 patients with chronic, stable HF from the GISSI-HF trial at baseline and 3 months.
  • Patients were followed for a median of 3.9 years for all-cause mortality.
  • Statistical analyses included univariable and multivariable regression, adjusting for established HF risk factors.

Main Results:

  • Circulating CgA levels correlated with known HF risk markers like age, diabetes, and renal function.
  • Univariable analysis showed a strong association between higher CgA levels and increased mortality risk.
  • After adjusting for established risk factors, the association between CgA and mortality was attenuated and no longer statistically significant.

Conclusions:

  • Circulating CgA levels in chronic, stable HF patients do not offer incremental prognostic information compared to standard clinical and biochemical assessments.
  • Current evidence suggests CgA is not a superior biomarker for predicting outcomes in HF.
  • Routine measurement of CgA is not recommended for prognostic purposes in stable chronic HF.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...